Healthcare
Live Price
Offline$15.76
+1.48% today
1Y Change
-23.69%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Schrödinger, Inc. (SDGR) is a Healthcare stock with a market cap of $930.00M and listed on NASDAQ. The stock last traded around $15.76 and down 23.7% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +23.3%, EPS growth of +45.1%, a dividend yield of 0.0%. What stands out right now is revenue +23.3%, EPS +45.1%, free cash flow +107.6% with operating margin -65.2% and ROIC -30.2%. Valuation is more restrained than many high-expectation growth names at price/sales 3.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SDGR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SDGR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SDGR Max Drawdown
-51.93%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SDGR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$137.9M
-23.8% YoY
FY Net Income
-$100.4M
+32.7% YoY
Free Cash Flow
-$77.8M
+39.0% YoY
Revenue Growth
+23.3%
EPS Growth
+45.1%
Gross Margin
55.7%
Net Margin
-40.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 256M | 208M | 217M | 181M | 138M |
| Gross Profit | 143M | 132M | 141M | 101M | 66M |
| Operating Income | -167M | -209M | -177M | -147M | -111M |
| EBITDA | -96M | -203M | -172M | -142M | -109M |
| Net Income | -103M | -187M | 41M | -149M | -100M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 231M | 147M | 155M | 90M | 120M |
| Total Assets | 726M | 823M | 803M | 689M | 756M |
| Total Liabilities | 362M | 402M | 254M | 241M | 199M |
| Shareholder Equity | 364M | 421M | 549M | 448M | 557M |
| Total Debt | 109M | 118M | 128M | 116M | 80M |
| Net Debt | -121M | -29M | -27M | 26M | -40M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
71M
+41.0% YoY
Capital Expenditures
7M
+10.6% YoY
Free Cash Flow
78M
+39.0% YoY
Key ratios
Gross Margin
55.7%
Operating Margin
-65.2%
Net Margin
-40.4%
ROE
-29.5%
Debt / Equity
0.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.